Nothing about a Futility Analysis , just the SSRA which I will bold.

Achieving full enrollment early leaves two major clinical reflection points that will transpire in 2018.  The first will be attaining 75% percent of our targeted 250 MACE events, being 188 events in total, thus allowing us the ability to conduct a sample size re-estimation analysis assuring that the trial will be sufficiently powered to confirm relative risk reduction,” stated Donald McCaffrey, President and Chief Executive Officer.  “The second major reflection point will be the most important, the Primary Endpoint read-out around the end of 2018. 

And here's the link:

https://globenewswire.com/news-release/2018/03/19/1441864/0/en/Resverlogix-Exceeds-Full-Enrollment-for-the-Pivotal-Phase-3-BETonMACE-Clinical-Trial.html